Company Overview
BrilliA Inc, through its subsidiaries, engages in the sales and marketing of lingerie products in North America, the European Union, the Asia Pacific, Latin America, the Middle East, and internationally. The company's products include active, sleep, and baby wear; period panties; panties; brassiere; bodysuits; dresses; swimsuits; tops; and other products under DIANA, Vanity Fair, Hanes, Wonderbra, Playtex, Bali, Maidenform, Jockey, Lands' End, fleur du mal, Kiki de Montparnasse, and Bra n Things brands. It sells through website, social media platforms, and marketplace platforms like Shopee. The company was incorporated in 2023 and is based in Singapore.
Why Investors Should Care
Return on capital employed stands at 21.3%.
Carries low leverage with a debt-to-equity ratio of 0.11.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -34.0%, earnings -14.2%.
- 5-Year Trend Long-term compounding — revenue CAGR -3.2%, profit CAGR -16.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -3.17% |
| 1 Year: | -34.00% |
Compounded Profit Growth
| 5 Years: | -16.19% |
| 1 Year: | -14.20% |
Stock Price Performance
| 1 Year: | -37.82% |
| 6 Months: | -23.71% |
| 3 Months: | +34.55% |
| 1 Month: | +7.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.71 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 21.3%.
- Generates positive free cash flow.
CONS
- Revenue declined at -3.2% CAGR over 5 years.
- Earnings shrank at -16.2% CAGR over 5 years.
- Trading 64.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Cyclical).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BRIA BrilliA Inc | 1.48 | -148.00 | $37.00M | - | 21.26% | -0.09% | -3.17% | -16.19% |
| 2 | AMZN Amazon.com, Inc. NDXSPXR3KAITECH | 256.97 | 20.66 | $2.77T | 0.00% | 13.33% | 30.56% | 24.04% | 32.72% |
| 3 | TSLA Tesla, Inc. NDXSPXR3KAI | 368.16 | 347.32 | $1.45T | 0.00% | 4.10% | 4.67% | 52.40% | 39.39% |
| 4 | HD The Home Depot, Inc. SPXR3K | 313.70 | 21.97 | $312.98B | 3.08% | 28.75% | 104.30% | 4.06% | 6.35% |
| 5 | BABA Alibaba Group Holding Limited AITECH | 112.66 | 25.43 | $280.03B | 0.93% | 4.16% | 6.36% | 5.62% | 12.49% |
| 6 | TM Toyota Motor Corporation | 191.45 | 8.46 | $226.71B | 3.23% | 5.24% | 12.40% | 10.91% | 16.22% |
| 7 | MCD McDonald's Corporation SPXR3K | 255.81 | 20.80 | $181.02B | 2.99% | 22.47% | - | 0.92% | 7.33% |
| 8 | TJX The TJX Companies, Inc. SPXR3K | 128.92 | 23.87 | $142.42B | 1.52% | 21.26% | 62.17% | 6.84% | 8.48% |
| 9 | BKNG Booking Holdings Inc. NDXSPXR3K | 180.30 | 20.03 | $139.71B | 0.87% | 70.23% | -96.88% | 16.93% | 22.07% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 70.92M | 52.93M | 55.96M | 64.39M | - |
| Cost of Revenue | 61.03M | 43.79M | 47.32M | 53.96M | - |
| Gross Profit | 9.89M | 9.13M | 8.64M | 10.43M | - |
| Operating Expenses | 4.02M | 3.67M | 4.04M | 6.26M | - |
| Operating Income | 5.86M | 5.47M | 4.60M | 4.17M | - |
| EBITDA | 6.06M | 5.67M | 4.58M | 4.58M | - |
| Interest Expense | 52.26K | 215.00K | 387.00K | 500.00K | - |
| Pretax Income | 5.79M | 5.24M | 3.99M | 3.62M | - |
| Tax Provision | 1.00M | 885.00K | 705.00K | 800.00K | - |
| Net Income | 4.78M | 4.35M | 3.28M | 2.81M | - |
| Diluted EPS | 0.24 | 0.19 | 0.15 | 0.12 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 24.93M | 22.20M | 27.15M | 28.41M |
| Current Assets | 24.92M | 22.20M | 26.20M | 25.69M |
| Cash & Equivalents | 4.36M | 8.91M | 6.38M | 7.70M |
| Inventory | 9.74M | 5.73M | 7.09M | 7.28M |
| Receivables | 6.21M | 2.33M | 6.59M | 7.55M |
| Total Liabilities | 16.30M | 15.71M | 19.05M | 10.33M |
| Current Liabilities | 16.30M | 15.71M | 19.05M | 9.04M |
| Long Term Debt | - | - | - | - |
| Total Debt | - | - | 0 | 1.68M |
| Total Equity | 8.63M | 6.50M | 8.09M | 18.06M |
| Shares Outstanding | 25.00M | 25.00M | 25.00M | 25.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 3.59M | 11.08M | 144.00K | -4.52M |
| Investing Cash Flow | -4.89K | -3.00K | 49.00K | -887.00K |
| Financing Cash Flow | -4.97M | -6.89M | -2.75M | 6.71M |
| Capital Expenditure | -4.89K | -9.00K | -57.00K | -72.00K |
| Free Cash Flow | 3.59M | 11.07M | 87.00K | -4.59M |
| Net Change in Cash | -1.39M | 4.19M | -2.56M | 1.30M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | 13.9% | 17.3% | 15.4% | 16.2% | - |
| Operating Margin % | 8.3% | 10.3% | 8.2% | 6.5% | - |
| Net Margin % | 6.7% | 8.2% | 5.9% | 4.4% | - |
| ROE % | 55.4% | 67.0% | 40.5% | 15.6% | - |
| ROCE % | 68.0% | 84.1% | 56.8% | 21.5% | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | - | 471 | $659 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BRIA
Nature Medicine features a BriaCell trial among 11 shaping medicine in 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQdFFXbzZ5NFpZTktMT0c0aDhUTm4xdjBJN0ZBQUxETUw4VmpiWDhJb0RFekJJUE9qMG1JUmNZcGpjdV9JUzhoczNPWkpaR1ZLaS05TWowSVkzTUN6R3hSRmlmNjZLQzRIQkpWX1FkLUhFaHJpMThES2RQMG9BNXhOR2dfQjhBZEwwMC1LZU…
DSMB Recommends Continuation of Bria-IMT Investigation in Metastatic Breast Cancer - OncLive
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQNy1qaE1jOEtDdlNHTEpQcWhJb09ONk1vclJEd1FfOGRKZzN0V3hPb0dvZHZleWhhQ1pub0VudGcyMHV4TGs5U1QwRXoyeGN1aUlwV3laTWs5eWRSM1djVkM0YVdEWVM4NlRKQ3lnTTRLOC10U09jZHNDaWpSQmFaSmowaU02eFNvNFhzMl…
BrilliA And 2 Other Penny Stocks To Consider For Your Watchlist - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxOVEVIbVdpM0VCZkNkbzFMTVRzTVpJOWFjeTBzVXZjeDJfS1RLc0hMLVFPQTd1TWt4cFVJd3lGZTFEZGRXcmlsNXBWbFVJaTlOZE1lTUVwSHROSkZkLTMyd195RG82WDlYcnd2cmxtcjI0Ui1jakJKWm1Qc2JXWnhIdExSd1FOYVEyWjU5UT…
BRIA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE90aVlmd29zblc4RE9uaXV3cXJlYmdya3FIdTI2WmhNbkkxd1Z4cFliZHUxWGJiaHBkbVlQVVJxWXFPN29Jc3c?oc=5" target="_blank">BRIA</a> <font color="#6f6f6f">Finviz</font>…
BrilliA Inc. Navigates Tariff Hit and Signals Growth Rebound in FY2026 Results - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxNdXhOdHBSOVEtZndPcEpqUWZpV0dRdEsxMzliQnlDc1gzRGtmUEt5cmZqUGFUdTZTSDA2aklqa2toZEN4cldDMm1JeHVNTTYwczNQZXFqdEUwLXNfTndBemNmeEVTY0Q4Nk5mWFZDQnVjS0k4b2tOZ0hDSVNCd1NJVUg1ckd2b2licjRlYj…
BriaCell Therapeutics Stock Rises 3.19% as Phase 3 Breast Cancer Trial and Bria-IMT Progress Draw Investor Interest - kalkine.ca
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxQcTBSWVhUdnRYT0RMUER1ZXIyQWswMlR0X21JdWpqTU9WWTVnaWR0QVpEd3hkaE9IWDlHeHBNa013Ry1NVW5nNmZMbjIxaktmXzF2R3Y3QW5laWZsZ1VtQkFSVm1JMmVueHpnTjBSaVZHZ0R3ZzNKV3Q1al9aN1N3ZFUtNjFGeWJfQ0Q3eF…
BRIA — Frequently Asked Questions
What is the current share price of BrilliA Inc (BRIA)?
As of 2026-09-19 21:16 PDT, BrilliA Inc (BRIA) trades at $1.48 on NYSE American. Its 52-week range is $1.10 to $4.15.
What is the market capitalisation of BRIA?
BrilliA Inc (BRIA) has a market capitalisation of $37.00M on NYSE American.
What is the P/E ratio of BRIA?
BRIA trades at a trailing price-to-earnings (P/E) ratio of -148.00. The industry average P/E is 18.98. Its price-to-book (P/B) ratio is 2.93.
What is the return on equity (ROE) of BRIA?
BRIA has a return on equity (ROE) of -0.09%. Its return on capital employed (ROCE) is 21.26%.
Is BRIA a good stock to buy?
This page provides a data-driven analysis of BrilliA Inc (BRIA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.